Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia

Dorte Vistisen, Bendix Carstensen, Patorno Elisabetta, Stefanie Lanzinger, Elise Chia-Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H.-H. Sheu, Cheli Melzer-Cohen, Reinhard W. Holl, Júlio Núñez, Kyoung Hwa Ha, Sigrun Halvorsen, Gisle Langslet, Avraham Karasik, Thomas Nyström, Leo Niskanen, Sonia Guleria, Riho Klement, Marc Carrasco, Johannes Foersch, Christina Shay, Lisette Koeneman, Fabian Hoti, Soulmaz Fazeli Farsani, Kamlesh Khunti, Francesco Zaccardi, Anuradhaa Subramanian, Krishnarajah Nirantharakumar, Unknown, Kimberly Brodovicz, Kristina Zint, Johannes Försch, Doron Rosenzweig, Maria Lajer, Mikkel Overgaard, Emilie Toresson Grip, Emma Söreskog, Joel Gunnarsson, Kristina Karlsdotter, Lotta Stenman, Mikko Tuovinen, Neus Valveny, Paula Casajust, Ruth Farmer, Andrew Ternouth, Anne Pernille Ofstad, Unknown, Masaomi Nangaku, Koichi Node, Yusuke Taneda, Atsutaka Yasui, Yutaka Seino, Jingbo Yi, Weiyu Lei, Sunwoo Lee, Jinhee Lee

Open source

DOI
10.1186/s12933-023-01963-9
Published
2023-08-31
Container
Cardiovascular Diabetology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12933-023-01963-9,
  title = {Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia},
  author = {Dorte Vistisen and Bendix Carstensen and Patorno Elisabetta and Stefanie Lanzinger and Elise Chia-Hui Tan and Daisuke Yabe and Dae Jung Kim and Wayne H.-H. Sheu and Cheli Melzer-Cohen and Reinhard W. Holl and Júlio Núñez and Kyoung Hwa Ha and Sigrun Halvorsen and Gisle Langslet and Avraham Karasik and Thomas Nyström and Leo Niskanen and Sonia Guleria and Riho Klement and Marc Carrasco and Johannes Foersch and Christina Shay and Lisette Koeneman and Fabian Hoti and Soulmaz Fazeli Farsani and Kamlesh Khunti and Francesco Zaccardi and Anuradhaa Subramanian and Krishnarajah Nirantharakumar and Unknown and Kimberly Brodovicz and Kristina Zint and Johannes Försch and Doron Rosenzweig and Maria Lajer and Mikkel Overgaard and Emilie Toresson Grip and Emma Söreskog and Joel Gunnarsson and Kristina Karlsdotter and Lotta Stenman and Mikko Tuovinen and Neus Valveny and Paula Casajust and Ruth Farmer and Andrew Ternouth and Anne Pernille Ofstad and Unknown and Masaomi Nangaku and Koichi Node and Yusuke Taneda and Atsutaka Yasui and Yutaka Seino and Jingbo Yi and Weiyu Lei and Sunwoo Lee and Jinhee Lee},
  year = {2023},
  journal = {Cardiovascular Diabetology},
  doi = {10.1186/s12933-023-01963-9},
  url = {https://doi.org/10.1186/s12933-023-01963-9}
}

RIS

TY  - JOUR
TI  - Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
AU  - Dorte Vistisen
AU  - Bendix Carstensen
AU  - Patorno Elisabetta
AU  - Stefanie Lanzinger
AU  - Elise Chia-Hui Tan
AU  - Daisuke Yabe
AU  - Dae Jung Kim
AU  - Wayne H.-H. Sheu
AU  - Cheli Melzer-Cohen
AU  - Reinhard W. Holl
AU  - Júlio Núñez
AU  - Kyoung Hwa Ha
AU  - Sigrun Halvorsen
AU  - Gisle Langslet
AU  - Avraham Karasik
AU  - Thomas Nyström
AU  - Leo Niskanen
AU  - Sonia Guleria
AU  - Riho Klement
AU  - Marc Carrasco
AU  - Johannes Foersch
AU  - Christina Shay
AU  - Lisette Koeneman
AU  - Fabian Hoti
AU  - Soulmaz Fazeli Farsani
AU  - Kamlesh Khunti
AU  - Francesco Zaccardi
AU  - Anuradhaa Subramanian
AU  - Krishnarajah Nirantharakumar
AU  - Unknown
AU  - Kimberly Brodovicz
AU  - Kristina Zint
AU  - Johannes Försch
AU  - Doron Rosenzweig
AU  - Maria Lajer
AU  - Mikkel Overgaard
AU  - Emilie Toresson Grip
AU  - Emma Söreskog
AU  - Joel Gunnarsson
AU  - Kristina Karlsdotter
AU  - Lotta Stenman
AU  - Mikko Tuovinen
AU  - Neus Valveny
AU  - Paula Casajust
AU  - Ruth Farmer
AU  - Andrew Ternouth
AU  - Anne Pernille Ofstad
AU  - Unknown
AU  - Masaomi Nangaku
AU  - Koichi Node
AU  - Yusuke Taneda
AU  - Atsutaka Yasui
AU  - Yutaka Seino
AU  - Jingbo Yi
AU  - Weiyu Lei
AU  - Sunwoo Lee
AU  - Jinhee Lee
PY  - 2023
JO  - Cardiovascular Diabetology
DO  - 10.1186/s12933-023-01963-9
UR  - https://doi.org/10.1186/s12933-023-01963-9
ER  -

APA

Vistisen, D., Carstensen, B., Elisabetta, P., Lanzinger, S., Tan, E. C., Yabe, D., Kim, D. J., Sheu, W. H., Melzer-Cohen, C., Holl, R. W., Núñez, J., Ha, K. H., Halvorsen, S., Langslet, G., Karasik, A., Nyström, T., Niskanen, L., Guleria, S., Klement, R., Carrasco, M., Foersch, J., Shay, C., Koeneman, L., Hoti, F., Farsani, S. F., Khunti, K., Zaccardi, F., Subramanian, A., Nirantharakumar, K., Unknown, Brodovicz, K., Zint, K., Försch, J., Rosenzweig, D., Lajer, M., Overgaard, M., Grip, E. T., Söreskog, E., Gunnarsson, J., Karlsdotter, K., Stenman, L., Tuovinen, M., Valveny, N., Casajust, P., Farmer, R., Ternouth, A., Ofstad, A. P., Unknown, Nangaku, M., Node, K., Taneda, Y., Yasui, A., Seino, Y., Yi, J., Lei, W., Lee, S., & Lee, J. (2023). Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-023-01963-9

Source records